Epithelial-Mesenchymal Transition and Somatic Alteration in Colorectal Cancer with and without Peritoneal Carcinomatosis

Shelygin, Yu. A.; Pospekhova, N. I.; Shubin, V. P.; Кашников, В. Н.; Фролов, С. А.; Сушков, О. И.; Ачкасов, С. И.; Цуканов, А. С.

doi:10.1155/2014/629496

Cited by 19 publications

(18 citation statements)

References 14 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The consequent colonization in distant organs requires the reversion of EMT and/or activation of the MET program to establish secondary tumors [19]. The frequent association between EMT and peritoneal carcinomatosis in CRC is a further proof that EMTpositive tumors have high metastatic potential, which is particularly important even at early stages of tumor growth [20]. The mechanisms for maintenance of mesenchymal state in CTCs are not fully understood, although it has been described that mesenchymal CTCs may be clustered with platelets, which represent the major source of circulating TGF-b production, a primary inducer of EMT [21].…”

Section: Liquid Biopsy and Molecular Subtypes Of Crc: Questioning Aboutmentioning

confidence: 99%

The rationale for liquid biopsy in colorectal cancer: a focus on circulating tumor cells

Gazzaniga

Raimondi

Nicolazzo

et al. 2015

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Capturing circulating tumor cells (CTCs) and/or circulating tumor DNA from blood, which represents a precious source of biological material derived from both primary and metastatic tumors, has been named a 'liquid biopsy'. While the circulating tumor DNA might be more representative of the bulk of the metastatic tumor, CTCs are thought to reflect more of the metastases-initiating cells. Consequently, a liquid biopsy made of tumor cells and tumor DNA that is able to track cancer evolution, as a fingerprint of the patient's individual tumor, and is easy to perform at every stage of the disease course, sounds attractive. This article mainly focuses on the applications of CTCs to track tumor dynamics in real time using colorectal cancer as a model system. The analysis of viable CTCs at DNA, RNA and protein levels, as well as their expansion in vitro, may allow deep investigation of the features of metastases-initiating cells.

show abstract

Section: Liquid Biopsy and Molecular Subtypes Of Crc: Questioning Aboutmentioning

confidence: 99%

The rationale for liquid biopsy in colorectal cancer: a focus on circulating tumor cells

Gazzaniga

Raimondi

Nicolazzo

et al. 2015

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

show abstract

“…8 The frequency of MSI in peritoneal carcinomatosis from CRC is likely low but should be tested for mucinous tumors. 12 …”

Section: Clinical Significance Of Microsatellite Instabilitymentioning

confidence: 99%

Genomics of peritoneal surface malignancies

2017

View full text Add to dashboard Cite

Peritoneal malignancies and metastasis are traditionally approached as a terminal disease, however with multiple lines of clinical therapy; long-term survival can be achieved in selected patients using aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. This is especially true for Pseudomyxoma peritonei from appendiceal neoplasms, peritoneal mesothelioma and peritoneal metastasis from colorectal cancer. In this article, we discuss the nature of genomic alterations in these three peritoneal malignancies and their potential as prognostic and therapeutic markers in clinical decisions. Genomic characterization of malignancies using technological advances including what is now widely used and accepted next-generation genomic sequencing methods has identified genomic anomalies (i.e. mutations, epigenetic modifications, transcription and expression changes in RNA) which is used for targeted therapy, prognostication, surveillance and prediction of response to therapy. BackgroundOngoing efforts to further characterize the genomics of peritoneal malignancies and metastasis remain essential. Although the appendix is considered as a part of the colon, its cancer genomic landscape is very different from colorectal cancer, suggesting that much like the variation in right and left-sided CRC, regional variation in gastrointestinal tract (GIT) tissues contributes to the unique disease phenotype. Equally, in Pseudomyxoma peritonei (PMP) of appendiceal origin, the most common gene mutations are in KRAS and GNAS. In addition, unlike CRC, DNA microsatellite instability and mutations in housekeeping DNA repair genes are typically rare (approximately 3%) and is therefore not a common phenotype of PMP. Research and discovery are still needed on genomic alterations driving peritoneal metastasis from CRC, although there is some evidence that BRAF mutations are associated with higher incidence of peritoneal metastasis. A better understanding of disease pathways linked with genomic alteration would contribute to our clinical goals of personalized medicine.

show abstract

“…Помимо глубины инвазии [9], с риском метастазирования связывают ряд других факторов: локализация опухоли и ее размер [10], ширина зоны инвазии [19], наличие лимфоваскулярной инвазии, венозной инвазии [5,8,15,18], опухолевый budding [14,17].…”

unclassified